Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
GEVA's Cash to Debt is ranked higher than
93% of the 841 Companies
in the Global Biotechnology industry.

( Industry Median: 60.34 vs. GEVA: No Debt )
Ranked among companies with meaningful Cash to Debt only.
GEVA' s 10-Year Cash to Debt Range
Min: 0.63  Med: 10000.00 Max: 58941
Current: No Debt
0.63
58941
Equity to Asset 0.96
GEVA's Equity to Asset is ranked higher than
96% of the 594 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. GEVA: 0.96 )
Ranked among companies with meaningful Equity to Asset only.
GEVA' s 10-Year Equity to Asset Range
Min: -4.72  Med: 0.74 Max: 0.98
Current: 0.96
-4.72
0.98
Interest Coverage No Debt
GEVA's Interest Coverage is ranked higher than
87% of the 375 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. GEVA: No Debt )
Ranked among companies with meaningful Interest Coverage only.
GEVA' s 10-Year Interest Coverage Range
Min: 7.93  Med: 10000.00 Max: 9999.99
Current: No Debt
7.93
9999.99
F-Score: 2
Z-Score: 158.40
M-Score: -3.67
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -3683.01
GEVA's Operating margin (%) is ranked lower than
86% of the 657 Companies
in the Global Biotechnology industry.

( Industry Median: -69.59 vs. GEVA: -3683.01 )
Ranked among companies with meaningful Operating margin (%) only.
GEVA' s 10-Year Operating margin (%) Range
Min: -6866.73  Med: -1191.95 Max: 120.8
Current: -3683.01
-6866.73
120.8
Net-margin (%) -3700.07
GEVA's Net-margin (%) is ranked lower than
87% of the 657 Companies
in the Global Biotechnology industry.

( Industry Median: -66.45 vs. GEVA: -3700.07 )
Ranked among companies with meaningful Net-margin (%) only.
GEVA' s 10-Year Net-margin (%) Range
Min: -7000  Med: -1205.62 Max: 81
Current: -3700.07
-7000
81
ROE (%) -37.34
GEVA's ROE (%) is ranked lower than
56% of the 761 Companies
in the Global Biotechnology industry.

( Industry Median: -29.50 vs. GEVA: -37.34 )
Ranked among companies with meaningful ROE (%) only.
GEVA' s 10-Year ROE (%) Range
Min: -105.21  Med: -53.53 Max: 52.19
Current: -37.34
-105.21
52.19
ROA (%) -35.53
GEVA's ROA (%) is ranked lower than
60% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: -25.57 vs. GEVA: -35.53 )
Ranked among companies with meaningful ROA (%) only.
GEVA' s 10-Year ROA (%) Range
Min: -74.33  Med: -44.77 Max: 32.45
Current: -35.53
-74.33
32.45
ROC (Joel Greenblatt) (%) -721.80
GEVA's ROC (Joel Greenblatt) (%) is ranked lower than
57% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: -333.14 vs. GEVA: -721.80 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
GEVA' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2491.51  Med: -1135.24 Max: 358.09
Current: -721.8
-2491.51
358.09
Revenue Growth (3Y)(%) -34.40
GEVA's Revenue Growth (3Y)(%) is ranked lower than
76% of the 404 Companies
in the Global Biotechnology industry.

( Industry Median: 0.30 vs. GEVA: -34.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
GEVA' s 10-Year Revenue Growth (3Y)(%) Range
Min: -70.4  Med: 20.30 Max: 158
Current: -34.4
-70.4
158
EBITDA Growth (3Y)(%) -11.20
GEVA's EBITDA Growth (3Y)(%) is ranked lower than
60% of the 427 Companies
in the Global Biotechnology industry.

( Industry Median: -3.90 vs. GEVA: -11.20 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
GEVA' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -79.9  Med: 4.95 Max: 30.9
Current: -11.2
-79.9
30.9
EPS Growth (3Y)(%) -11.80
GEVA's EPS Growth (3Y)(%) is ranked lower than
55% of the 413 Companies
in the Global Biotechnology industry.

( Industry Median: -7.70 vs. GEVA: -11.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
GEVA' s 10-Year EPS Growth (3Y)(%) Range
Min: -78.5  Med: 3.55 Max: 30.5
Current: -11.8
-78.5
30.5
» GEVA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

GEVA Guru Trades in Q3 2014

Jim Simons 26,200 sh (New)
Columbia Wanger 3,927,006 sh (+11.53%)
» More
Q4 2014

GEVA Guru Trades in Q4 2014

Columbia Wanger 3,847,094 sh (unchged)
Jim Simons Sold Out
Columbia Wanger 3,847,094 sh (-2.03%)
» More
Q1 2015

GEVA Guru Trades in Q1 2015

Columbia Wanger 3,245,542 sh (-15.64%)
» More
2015

GEVA Guru Trades in 2015

Columbia Wanger 0 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with GEVA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 12.01
GEVA's P/B is ranked lower than
82% of the 747 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. GEVA: 12.01 )
Ranked among companies with meaningful P/B only.
GEVA' s 10-Year P/B Range
Min: 0.76  Med: 4.27 Max: 17.16
Current: 12.01
0.76
17.16
P/S 1325.56
GEVA's P/S is ranked lower than
98% of the 591 Companies
in the Global Biotechnology industry.

( Industry Median: 11.60 vs. GEVA: 1325.56 )
Ranked among companies with meaningful P/S only.
GEVA' s 10-Year P/S Range
Min: 1.04  Med: 14.37 Max: 1325.56
Current: 1325.56
1.04
1325.56
Current Ratio 25.93
GEVA's Current Ratio is ranked higher than
94% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: 4.37 vs. GEVA: 25.93 )
Ranked among companies with meaningful Current Ratio only.
GEVA' s 10-Year Current Ratio Range
Min: 3.17  Med: 8.35 Max: 54.89
Current: 25.93
3.17
54.89
Quick Ratio 25.93
GEVA's Quick Ratio is ranked higher than
94% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. GEVA: 25.93 )
Ranked among companies with meaningful Quick Ratio only.
GEVA' s 10-Year Quick Ratio Range
Min: 3.17  Med: 8.35 Max: 54.89
Current: 25.93
3.17
54.89
Days Sales Outstanding 57.94
GEVA's Days Sales Outstanding is ranked higher than
53% of the 558 Companies
in the Global Biotechnology industry.

( Industry Median: 60.65 vs. GEVA: 57.94 )
Ranked among companies with meaningful Days Sales Outstanding only.
GEVA' s 10-Year Days Sales Outstanding Range
Min: 0.32  Med: 63.44 Max: 490.14
Current: 57.94
0.32
490.14

Valuation & Return

vs
industry
vs
history
Price/Net Cash 13.04
GEVA's Price/Net Cash is ranked lower than
65% of the 451 Companies
in the Global Biotechnology industry.

( Industry Median: 8.40 vs. GEVA: 13.04 )
Ranked among companies with meaningful Price/Net Cash only.
GEVA' s 10-Year Price/Net Cash Range
Min: 1.09  Med: 6.91 Max: 220.96
Current: 13.04
1.09
220.96
Price/Net Current Asset Value 12.81
GEVA's Price/Net Current Asset Value is ranked lower than
66% of the 538 Companies
in the Global Biotechnology industry.

( Industry Median: 7.59 vs. GEVA: 12.81 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
GEVA' s 10-Year Price/Net Current Asset Value Range
Min: 1.02  Med: 6.77 Max: 37.78
Current: 12.81
1.02
37.78
Price/Tangible Book 12.18
GEVA's Price/Tangible Book is ranked lower than
75% of the 687 Companies
in the Global Biotechnology industry.

( Industry Median: 5.90 vs. GEVA: 12.18 )
Ranked among companies with meaningful Price/Tangible Book only.
GEVA' s 10-Year Price/Tangible Book Range
Min: 1.01  Med: 5.69 Max: 19.37
Current: 12.18
1.01
19.37
Price/Projected FCF 322.43
GEVA's Price/Projected FCF is ranked lower than
100% of the 157 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. GEVA: 322.43 )
Ranked among companies with meaningful Price/Projected FCF only.
GEVA' s 10-Year Price/Projected FCF Range
Min: 0.01  Med: 5.81 Max: 362
Current: 322.43
0.01
362
Price/Median PS Value 92.12
GEVA's Price/Median PS Value is ranked lower than
100% of the 540 Companies
in the Global Biotechnology industry.

( Industry Median: 1.19 vs. GEVA: 92.12 )
Ranked among companies with meaningful Price/Median PS Value only.
GEVA' s 10-Year Price/Median PS Value Range
Min: 0.11  Med: 4.58 Max: 51.17
Current: 92.12
0.11
51.17
Earnings Yield (Greenblatt) (%) -2.60
GEVA's Earnings Yield (Greenblatt) (%) is ranked higher than
62% of the 813 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. GEVA: -2.60 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
GEVA' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -2.6  Med: 43.20 Max: 3528.7
Current: -2.6
-2.6
3528.7

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:TMS1.Germany,
Synageva BioPharma Corp is incorporated in Delaware in 1993. On November 2, 2011, Trimeris, Inc., a Delaware corporation closed a merger transaction, Reverse Merger with Synageva BioPharma Corp., Pursuant to the Merger Agreement, Private Synageva became a wholly owned subsidiary of Trimeris. As a Reverse Merger, Trimeris changed its name to Synageva BioPharma Corp. The Company is a biopharmaceutical company focused on the discovery, development, and commercialization of therapeutic products for patients with rare diseases. The Company has several proteins therapeutic in its pipeline, including enzyme replacement therapies for lysosomal storage diseases (LSDs) and protein therapeutic programs for other rare diseases that are at the stage of preclinical development. Its program, sebelipase alfa is a recombinant human lysosomal acid lipase deficiency (LAL Deficiency), currently evaluating in global Phase 3 clinical trials in infants, children and adults with LAL Deficiency. LAL Deficiency is rare autosomal recessive LSD characterized by decreased LAL enzyme activity leading to intracellular accumulation of lipids. This disease leads to medical complications with significant morbidity and early mortality. Sebelipase alfa has been granted orphan designation by the FDA, the EMA, and the Japanese Ministry of Health, Labour and Welfare. Additionally, sebelipase alfa has received Fast Track Designation by the FDA, and Breakthrough Therapy designation by the FDA for LAL Deficiency presenting in infants. The Company has not yet received approval to market this product and is not currently commercializing any other products. Sebelipase alfa is a recombinant form of the human LAL enzyme under development as an enzyme replacement therapy for LAL Deficiency. The Company is currently enrolling and dosing Phase 3 Trial of Sebelipase Alfa in Children and Adults with LAL Deficiency. It is also pursuing a development strategy for sebelipase alfa to assess safety and tolerability in a broad population of patients, including infants, children, and adults, and to demonstrate efficacy, safety and tolerability of sebelipase alfa in the treatment of LAL Deficiency. Its potential competitors include large pharmaceutical and biotechnology companies and specialty pharmaceutical companies, academic institutions, government agencies, and research institutions. The preclinical studies and clinical testing, manufacture, labeling, storage, record keeping, advertising, promotion, export, and marketing, among other things, of its product candidates and future products, are subject to extensive regulation by governmental authorities in the U.S. and other countries.
» More Articles for GEVA

Headlines

Articles On GuruFocus.com
Alexion Acquiring Synageva For $8.4 Billion May 09 2015 
Wednesday Pre-Market Insights: GEVA, BRDR, MGI, NDLS, ZU May 06 2015 

More From Other Websites
Alexion Facing Big Costs, Guidance Disappoints Jul 30 2015
Ultragenyx Downgraded At Morgan Stanley, Valuation 'Stretched' And Pipeline Faces Execution Risk Jul 27 2015
Synageva Biopharma Corp (GEVA) Acquisition Helps Baker Bros. Advisors Top All Others In Q2 Returns Jul 10 2015
ALEXION PHARMACEUTICALS, INC. Financials Jun 26 2015
SYNAGEVA BIOPHARMA CORP Files SEC form 8-K, Completion of Acquisition or Disposition of Assets,... Jun 23 2015
Alexion Completes Acquisition of Synageva Jun 23 2015
Alexion Accepts Shares of Synageva BioPharma Corp. Tendered Into Exchange Offer Jun 22 2015
GEVA helped advance Sectoral Asset 9.4% in May. ALXN did not Jun 17 2015
5 Healthy Stocks in the Top Biotech ETF - ETF News And Commentary Jun 17 2015
The Only Way to Play Biotech Buyouts Jun 09 2015
Synageva BioPharma Completes Targeted Enrollment in Phase 1/2 Trial with SBC-103 for... Jun 04 2015
SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of The Board of Directors of... Jun 02 2015
Alexion and Synageva Announce Early Termination of Hart-Scott-Rodino Waiting Period for Alexion’s... May 29 2015
The Synageva BioPharma–Alexion Deal Spread Has Some Hair on It May 27 2015
Synageva BioPharma Files for Kanuma's Approval in Japan - Analyst Blog May 27 2015
Synageva BioPharma Submits Kanuma™ (Sebelipase Alfa) Application For LAL Deficiency In Japan May 26 2015
4 Big Biotech Companies to Sell Now May 26 2015
SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of The Board of Directors of... May 22 2015
Pall-Danaher Transaction: What You Should Know about Danaher May 21 2015
Pall-Danaher Transaction: An Overview of Pall May 21 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK